{"id":564159,"date":"2026-09-25T12:30:00","date_gmt":"2026-09-25T10:30:00","guid":{"rendered":"https:\/\/medizinonline.com\/?p=564159"},"modified":"2026-09-04T09:31:32","modified_gmt":"2026-09-04T07:31:32","slug":"petites-molecules-a-usage-topique-les-januskinases-ou-la-pde-4-comme-cibles","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/fr\/petites-molecules-a-usage-topique-les-januskinases-ou-la-pde-4-comme-cibles\/","title":{"rendered":"\u00ab Petites mol\u00e9cules \u00bb \u00e0 usage topique : les januskinases ou la PDE-4 comme cibles ?"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Les cibles intracellulaires, en tant que points d\u2019action th\u00e9rapeutiques des m\u00e9dicaments de faible poids mol\u00e9culaire dans le traitement de la dermatite atopique (DA), ont pris de l\u2019importance, et la formulation topique garantit un effet pharmacologique local, ce qui favorise un profil de s\u00e9curit\u00e9 avantageux [1,2]. Dans certains pays, les inhibiteurs topiques de la Janus kinase (JAK) destin\u00e9s au traitement de la DA ont franchi les \u00e9tapes de l\u2019autorisation de mise sur le march\u00e9 ; ainsi, le delgocitinib est autoris\u00e9 au Japon et le ruxolitinib l\u2019est depuis peu dans l\u2019Union europ\u00e9enne, en plus des \u00c9tats-Unis. En ce qui concerne les inhibiteurs topiques de la phosphodiest\u00e9rase (PDE) 4, outre le crisaborol et le roflumilast, le difamilast a lui aussi r\u00e9cemment obtenu une autorisation de la FDA.  <\/strong><\/p>\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/fr\/mon-compte\/paquets\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/fr\/se-connecter\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Ffr%2Fpetites-molecules-a-usage-topique-les-januskinases-ou-la-pde-4-comme-cibles%2F\">Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Les cibles intracellulaires, en tant que points d\u2019action th\u00e9rapeutiques des m\u00e9dicaments de faible poids mol\u00e9culaire dans le traitement de la dermatite atopique (DA), ont pris de l\u2019importance, et la formulation&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/fr\/mon-compte\/paquets\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/fr\/se-connecter\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Ffr%2Fpetites-molecules-a-usage-topique-les-januskinases-ou-la-pde-4-comme-cibles%2F\">Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":564160,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Dermatite atopique chez les enfants et les adultes  ","footnotes":"","_members_access_role":[],"_members_access_error":""},"category":[11549,11349,11362,11527,11531,11464],"tags":[94944,100166,80607,12636,80606,100165,68790,100164,15564,100167,100168,73258,80605,12617,100163],"powerkit_post_featured":[],"class_list":["post-564159","post","type-post","status-publish","format-standard","has-post-thumbnail","category-rx-fr","category-allergologie-et-immunologie-clinique","category-dermatologie-et-venerologie","category-etudes","category-formation-continue","category-pharmacologie-et-toxicologie","tag-crisaborol","tag-crisade-control","tag-delgocitinib-fr","tag-dermatite-atopique-fr","tag-difamilast-fr","tag-integument","tag-januskinases","tag-pde-4","tag-petites-molecules","tag-qba4-1","tag-qba4-2","tag-roflumilast-fr","tag-ruxolitinib-fr","tag-therapie-topique","tag-true-ad","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-10-02 12:38:20","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"fr_FR","wpml_translations":{"it_IT":{"locale":"it_IT","id":564165,"slug":"piccole-molecole-per-uso-topico-le-chinasi-janus-o-la-pde-4-come-bersaglio","post_title":"\u00abPiccole molecole\u00bb per uso topico: le chinasi Janus o la PDE-4 come bersaglio?","href":"https:\/\/medizinonline.com\/it\/piccole-molecole-per-uso-topico-le-chinasi-janus-o-la-pde-4-come-bersaglio\/"},"pt_PT":{"locale":"pt_PT","id":564271,"slug":"pequenas-moleculas-de-aplicacao-topica-as-janus-quinases-ou-a-pde-4-como-alvo","post_title":"\u00abPequenas mol\u00e9culas\u00bb de aplica\u00e7\u00e3o t\u00f3pica: as janus-quinases ou a PDE-4 como alvo?","href":"https:\/\/medizinonline.com\/pt-pt\/pequenas-moleculas-de-aplicacao-topica-as-janus-quinases-ou-a-pde-4-como-alvo\/"},"es_ES":{"locale":"es_ES","id":564282,"slug":"moleculas-pequenas-de-aplicacion-topica-las-janusquinasas-o-la-pde-4-como-diana","post_title":"\u00abMol\u00e9culas peque\u00f1as\u00bb de aplicaci\u00f3n t\u00f3pica: \u00bflas janusquinasas o la PDE-4 como diana?","href":"https:\/\/medizinonline.com\/es\/moleculas-pequenas-de-aplicacion-topica-las-janusquinasas-o-la-pde-4-como-diana\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/564159","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/comments?post=564159"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/564159\/revisions"}],"predecessor-version":[{"id":564164,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/564159\/revisions\/564164"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media\/564160"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media?parent=564159"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/category?post=564159"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/tags?post=564159"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/powerkit_post_featured?post=564159"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}